• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.

作者信息

Verbist L

机构信息

Diagnostic Microbiology Laboratory, Univ. Hosp. St. Rafaël, Leuven, Belgium.

出版信息

J Antimicrob Chemother. 1987 Sep;20(3):363-72. doi: 10.1093/jac/20.3.363.

DOI:10.1093/jac/20.3.363
PMID:3119552
Abstract

The in-vitro activity of Ro 23-6240, a new quinolone, was tested in comparison with that of other quinolones against 486 recent clinical isolates. Ro 23-6240 displayed the typical features of the new quinolones: highest activity against Gram-negative bacilli, MBCs close to the MICs, minimum inoculum effect and rapid killing. Against Gram-negative organisms (Enterobacteriaceae, non-fermenters, Haemophilus influenzae and gonococci) the activity of Ro 23-6240 was between that of ofloxacin and norfloxacin; against staphylococci its activity was between that of ciprofloxacin and ofloxacin, and against streptococci it was similar to that of norfloxacin.

摘要

相似文献

1
Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
J Antimicrob Chemother. 1987 Sep;20(3):363-72. doi: 10.1093/jac/20.3.363.
2
Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.培氟沙星、氧氟沙星、依诺沙星和环丙沙星对256株临床分离株的体外活性比较
Acta Pathol Microbiol Immunol Scand B. 1987 Apr;95(2):141-6. doi: 10.1111/j.1699-0463.1987.tb03102.x.
3
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.八种新型喹诺酮类药物与萘啶酸的体外活性比较
J Antimicrob Chemother. 1986 Nov;18 Suppl D:1-20. doi: 10.1093/jac/18.supplement_d.1.
4
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].[10种新型4-喹诺酮类药物对肠道致病菌的体外活性比较]
Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):800-4.
5
Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.新型4-喹诺酮衍生物RO 23-6240（氟罗沙星）的体外活性比较
Eur J Clin Microbiol. 1987 Aug;6(4):482-5. doi: 10.1007/BF02013116.
6
In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.新型氟喹诺酮RO 23-6240（AM-833）的体外活性
Diagn Microbiol Infect Dis. 1987 Apr;6(4):293-9. doi: 10.1016/0732-8893(87)90178-7.
7
[In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].新型喹诺酮类药物对非发酵菌的体外活性及敏感性试验参考
Infection. 1986;14 Suppl 3:S191-5. doi: 10.1007/BF01667842.
8
In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.需氧革兰氏阴性血培养分离株对恶喹酸、诺氟沙星、环丙沙星、依诺沙星、培氟沙星、氧氟沙星和氧恶喹酸的体外敏感性
Infection. 1986 May-Jun;14(3):142-4. doi: 10.1007/BF01643481.
9
In-vitro selection of bacteria resistant to the 4-quinolone agents.
J Antimicrob Chemother. 1987 Jan;19(1):65-71. doi: 10.1093/jac/19.1.65.
10
In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.A-56619、A-56620、阿米氟沙星、环丙沙星、依诺沙星、诺氟沙星和氧氟沙星对耐甲氧西林金黄色葡萄球菌的体外比较
Antimicrob Agents Chemother. 1986 Feb;29(2):325-6. doi: 10.1128/AAC.29.2.325.

引用本文的文献

1
Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.性别对氟罗沙星和环丙沙星与咖啡因药代动力学相互作用的影响。
Clin Pharmacokinet. 2003;42(11):985-96. doi: 10.2165/00003088-200342110-00004.
2
Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.氟罗沙星单独及与克林霉素或甲硝唑联合应用在实验性腹腔脓肿中的活性。
Antimicrob Agents Chemother. 1994 Feb;38(2):252-5. doi: 10.1128/AAC.38.2.252.
3
Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.
氟罗沙星。对其在各种感染中的药理学及治疗效果的综述。
Drugs. 1995 May;49(5):794-850. doi: 10.2165/00003495-199549050-00010.
4
Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.单次及多次服用400毫克和800毫克剂量氟罗沙星后的药代动力学及组织渗透情况。
Antimicrob Agents Chemother. 1988 Oct;32(10):1515-20. doi: 10.1128/AAC.32.10.1515.
5
Fluoroquinolone antimicrobial agents.氟喹诺酮类抗菌剂。
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
6
Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.喹诺酮类药物的进展。几种研究中的喹诺酮衍生物的细菌学、药代动力学及初步临床经验。
Pharm Weekbl Sci. 1989 Apr 28;11(2):33-43. doi: 10.1007/BF01962973.
7
Fleroxacin resistance in Escherichia coli.大肠杆菌中的氟罗沙星耐药性
Antimicrob Agents Chemother. 1989 Feb;33(2):239-41. doi: 10.1128/AAC.33.2.239.
8
Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.氟罗沙星在皮肤及皮肤结构感染患者中的稳态药代动力学。
Antimicrob Agents Chemother. 1990 May;34(5):922-3. doi: 10.1128/AAC.34.5.922.
9
Fleroxacin clinical pharmacokinetics.氟罗沙星的临床药代动力学。
Clin Pharmacokinet. 1992 Feb;22(2):116-31. doi: 10.2165/00003088-199222020-00003.